Biocon Ltd., India’s leading biopharmaceutical company, has taken a major step in its global expansion strategy by inaugurating a state-of-the-art manufacturing facility in the United States. The facility, located in Cranbury, New Jersey, is operated by Biocon Generics Inc., a wholly-owned subsidiary of Biocon.

Strategic Investment

The facility, originally acquired from Eywa Pharma Inc. in 2023, represents a USD 30 million investment. It specializes in Oral Solid Dosage (OSD) formulations and has an impressive annual production capacity of 2 billion tablets. With a few products already commercialized and more in the pipeline, this expansion strengthens Biocon’s manufacturing base while reinforcing its supply chain resilience.

Kiran Mazumdar-Shaw, Chairperson of Biocon Group, emphasized that the New Jersey facility marks a new chapter in Biocon’s global journey, underscoring the company’s ambitions to diversify, innovate, and grow internationally.

Key Data at a Glance

Aspect	Details
Location	Cranbury, New Jersey, U.S.
Subsidiary	Biocon Generics Inc. (wholly-owned subsidiary of Biocon Ltd.)
Acquisition	Facility acquired from Eywa Pharma Inc. in 2023
Investment	Over USD 30 million
Facility Type	Oral Solid Dosage (OSD) manufacturing plant
Annual Capacity	2 billion tablets
Commercialization	Few products launched, more under development
Strategic Purpose	Diversify manufacturing, strengthen supply chain, accelerate global growth

Future Expansion Plans

Biocon’s U.S. manufacturing launch is part of a broader strategy, which includes:

1. Enhanced Manufacturing Capabilities – Increasing production capacity across facilities to meet growing global demand.
2. Pipeline Expansion – Actively commercializing products and developing a strong portfolio to diversify offerings.
3. Global Market Penetration – Strengthening Biocon’s presence in international markets, with a sharper focus on developed economies.
4. Healthcare Commitment – Engaging with providers and innovators to ensure broader, equitable access to affordable healthcare.
5. Product Diversification – Exploring R&D and collaborations to expand into new therapeutic areas.

Outlook

The establishment of the Cranbury facility positions Biocon as a stronger global player in the biopharmaceutical and generics industry. With investments in infrastructure, product innovation, and global partnerships, the company is charting a course toward becoming a leading provider of affordable and accessible medicines worldwide.